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To assess antiarrhythmic efficacy of oral nadolol, 15
patients with recurrent supraventricular tachycardia were
studied. Eight patients had atrioventricular (AV) nodal
reentrant tachycardia and seven had AV reciprocating
tachycardia involving an accessory AV pathway. Elec-
trophysiologic studies were performed before and after
intravenous infusion of propranolol (0.20 mg/kg), and
were repeated 5 to 8 days after oral nadolol therapy at
a daily dose of 80 to 160 mg. Both intravenous pro-
pranolol and oral nadolol induced significant prolon-
gation of the sinus cycle length from 741 ± 73 ms to
834 ± 97 and 1,029 ± 95 ms, respectively (p < 0.001
and p < 0.0001, respectively). Both intravenous pro-
pranolol and oral nadolol depressed AV nodal but not
accessory AV pathway conduction, and shifted the dual
AV nodal pathway conductioncurves (AIAz, AzHz; AIAz,
Nadolol (Corgard) is a noncardioselective, beta-adreno-
ceptor blocking agent. It has a plasma half-life of 14 to
24 hours (1-3). The long plasma half-life allows single,
daily doses in clinical use. Several clinical studies (4-8)
demonstrated that oral nadolol administered once a day was
efficacious in the treatment of hypertension and angina
pectoris.
Nadolol, like other beta-adrenoceptor blocking agents,
has also been shown to possess antiarrhythmic properties
(9); however, clinical information regarding its effects on
cardiac arrhythmias is scarce. In a preliminary report, Vuk-
ovich et al. (10) observed that oral nadolol suppressed ven-
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HIHz) upward and to the right by prolonging the con-
duction time and increasing the refractory period. Ten
patients (seven with AV nodal reentry and three with
AV reciprocation) who responded to intravenous pro-
pranolol also responded to oral nadolol with loss of the
inducibility of sustained tachycardia; the remaining five
patients (one with AV nodal reentry and four with AV
reciprocation) who did not respond to intravenous pro-
pranolol also failed to respond to oral nadolol with per-
sistence of the inducibility of sustained tachycardia.
Thus, in conclusion, intravenous propranolol testing
predicts the therapeutic efficacy of oral nadolol therapy
and oral nadolol in once-daily doses may be used for
long-term prophylaxis of recurrent supraventricular
tachycardia.
tricular premature beats, slowed the rate of sinus tachycardia
and reduced the ventricular response of atrial tachycardia
and atrial flutter-fibrillation. In the present study, we as-
sessed the electrophysiologic effects of oral nadolol in 15
patients with recurrent paroxysmal supraventricular tachy-
cardia. Furthermore, we compared these effects with those
of intravenous propranolol during electrophysiologic studies
to determine if the response to intravenous propranolol pre-
dicts the efficacy of oral nadolol therapy.
Methods
Study patients. Fifteen patients with recurrent parox-
ysmal supraventricular tachycardia were enrolled in the study.
The subjects consisted of eight men and seven women rang-
ing in age from 17 to 65 (mean 40.5) years. All had symp-
toms of palpitation or dizziness, or both, during the tachy-
cardia. Their clinical data are summarized in Table I. We
excluded those patients whose clinical condition was un-
stable and in whom beta-adrenoceptor blockade was con-
traindicated because of associated bronchial asthma, chronic
0735-1097/83/$3.00
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obstructive pulmonary disease, congestive heart failure and
sick sinus syndrome. We also excluded patients in whom
only nonsustained supraventricular tachycardia (self-ter-
minating within 10 minutes) was inducible during control
electrophysiologic studies.
Electrophysiologic study. All patients gave informed
written consent and antiarrhythmic drugs were discontinued
in all 48 to 72 hours before the study. The study was per-
formed with patients in a postabsorptive, nonsedated state.
With a conventional method (11), a tripolar electrode cath-
eter was introduced from the right femoral vein and placed
in the right atrium against the septal leaflet of the tricuspid
valve to record the His bundle electrogram. One quadripolar
electrode catheter was introduced from the left antecubital
or left subclavian vein and placed in the coronary sinus
to record the left atrial electrogram. Additionally, two quad-
ripolar electrode catheters were introduced from the right
or left femoral vein and placed in the high right atrium and
right ventricle, respectively, for programmed electrical
stimulation. Intracardiac electrograms were simultaneously
displayed with electrocardiographic leads I, II and VI on a
multichannel oscilloscopic recorder (Electronics for Medi-
cine, VR-12) and were recorded at a paper speed of 100
mm/s using a filter frequency setting of 30 to 500 Hz.
A programmed digital stimulator (Bloom and Associates)
was used to deliver electrical impulses of 2.0 ms at ap-
proximately twice diastolic threshold. As previously de-
scribed (12), programmed electrical stimulation consisting
of atrial and ventricular incremental pacing and extrastim-
ulation was first performed to ascertain anterograde and
retrograde atrioventricular (AV) conduction patterns and the
inducibility of supraventricular tachycardia (12-15).
Table 1. Clinical Data
ASSOCIated
Age (yr) Duratron (yr) Cardiovascular
Case &Sex of Recurrent SVT DIsease
I 19M 6
2 65M 10 Hypertension
3 25F 4
4 48F 5
5 59M 3 Hypertension
6 26F 10
7 51F 1
8 37F 21
9 52M 15 ASHD
10 19F 6
II 42M 4 Hypertension
12 62F 10 ASHD
13 17M 4
14 38M 2
15 37F 7
ASHD = arteriosclerotic heart disease, F = female, M = male; SVT
= supraventricular tachycardia; - = absent.
Administration of intravenous propranolol. After
control data were obtained, propranolol was intravenously
infused at 1 mg/min up to a total dose of 0.2 mg/kg body
weight while vital signs were closely monitored. This dos-
age of intravenous propranolol was chosen to achieve a
significant beta-adrenoceptor blockade as suggested by Jose
and Taylor (16). Programmed electrical stimulation was
then repeated 10 minutes later to assess the effects of in-
travenous propranolol. In each patient the time required to
complete the repeat study was approximately 15 minutes.
The plasma concentration of propranolol was not measured.
Administration of oral nadolol and repeat electro-
physiologic study. After evaluation of the effects of intra-
venous propranolol, all intracardiac catheters were removed
and all patients returned to the ward for observation. Nadolol
was given orally as a once-daily dose of approximately
1.5 to 2.0 mg/kg (80 to 160 mg). The dose was titrated
depending on patient tolerance but ideally achieving a heart
rate at rest of 50 to 65 beats/min. After 5 to 8 (mean 6.8)
days of nadolol therapy (4), all patients underwent a repeat
electrophysiologic study. Although the plasma concentra-
tion of nadolol was also not measured, oral nadolol therapy
for a similar duration was previously shown to be sufficient
to attain a steady state of plasma nadolol concentrations
(4,17). During the repeat study, only two quadripolar elec-
trode catheters were intravenously inserted. The study was
performed before the next scheduled dose of oral nadolol.
One electrode catheter was placed in the high right atrium
for pacing and recording, and the other was first placed in
the low septal right atrium for recording the His bundle
electrogram during programmed high right atrial stimula-
tion. This latter electrode catheter was then placed in the
right ventricle for programmed right ventricular stimulation
during which only the high right atrial (not the His bundle)
electrogram was recorded. The driving cycle lengths for
both programmed atrial and ventricular stimulation were the
same as those used before and after intravenous infusion of
propranolol in each patient.
Electrophysiologic data. The definition and measure-
ment of AV conduction intervals in both anterograde and
retrograde directions were conventional (12-15). Electro-
physiologic mechanisms responsible for supraventricular
tachycardia were delineated during the control study. The
diagnostic criteria for AV nodal reentry and AV recipro-
cation involving an accessory pathway were as previously
described (12-15). Because only two electrode catheters
were used to study the effects of oral nadolol therapy, only
relevant and comparable electrophysiologic data are pre-
sented. These include:
1) Sinus cycle length before each electrophysiologic study.
2) Inducibility, cycle length and sustainability of tachy-
cardia with reference to atrial and ventricular echo zones
caused by AV nodal reentry or AV reciprocation involving
an accessory AV pathway.
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3) Anterograde conduction properties such as: a) effective
and functional refractory periods of the slow and fast AV
nodal pathways and the critical AV nodal conduction time
required to initiate AV nodal reentry in patients with dual
AV nodal pathways , and b) effective refractory periods of
the AV node and accessory AV pathway in patients with
the Wolff-Parkinson-White syndrome .
4) Retrograde conduction properties such as: a) ventri-
culoatrial (VA) conduction time during the basic ventricular
drive (measured from the stimulus to the onset of the high
right atrial electrogram), and b) effective refractory periods
of the VA conduction system or accessory AV pathway
(AP), or both .
Statistical analysis. The data are presented as mean val-
ues ± I standard deviation, and the paired t test was used
to analyze changes in cycle length, conduction time and
refractory period.
Results
Responses to propranolol and nadolol. All IS patients
tolerated intravenous infusion of propranolol (0.2 mg/kg)
well and none of them developed bronchospasm, hypoten-
sion, congestive heart failure or symptomatic bradycardia.
During oral nadolol therapy, three patients (Cases 5, 8 and
14) became symptomatic with dizziness associated with sinus
bradycardia at a rate of 40 to SO/min. The symptoms were
mild and all resolved after reduction of the daily dosage of
nadolol to 80 mg (from 120 to 160 mg) before the repeat
electrophysiologic study.
All patients had inducible sustained tachycardia (nonself-
terminating, lasting longer than 10 minutes) during the con-
trol study: eight patients had atrioventricular (AV) nodal
reentrant tachycardia (group I) and the remaining seven had
AV reciprocating tachycardia using an accessory AV path-
way for retrograde conduction (group II). Both intravenous
propranolol and oral nadolol induced a significant slowing
of the rest sinus rate before the repeat electrophy siologic
study (sinus cycle length lengthened from 741 ± 73 to 834
± 97 ms after propranolol , probability [p] < 0.001 ; and to
1,029 ± 95 ms after nadolol , p < 0.0001) (Tables 2 and
3), and both drugs suppressed the inducibility of sustained
tachycardia in 10 of the IS patients. The response to intra-
venous propranolol seemed to predict results of oral nadolol
therapy. Detailed electrophysiologic data are summarized
in Tables 2 and 3.
AV Nodal Reentrant Tachycardia (Group 1)
Of the eight patients with AV nodal reentrant tachy-
cardia , seven (Cases 2, 3, 8, 11, 12, 14 and IS) manifested
the slow-fast form of AV nodal reentry using a slow AV
nodal pathway for anterograde conduction and a fast AV
nodal pathway for retrograde conduction , and the remaining
patient (Case 5) manifested the fast-slow form with a re-
versed AV nodal reentrant circuit.
Inducibility of AV nodal reentrant tachycardia.
During the control study , induction of sustained AV nodal
reentrant tachycardia of the slow-fast form was possible with
programmed atrial extrastimulation in all patients except the
one (Case 5) with the fast-slow form of AV nodal reentry
(Table 2). In three (Cases 8, 12 and 15) of the seven patients,
the tachycardia could also be initiated by rapid atrial pacing.
An atrial echo zone associated with dual AV nodal pathway
conduction (discontinuous A.Az, AzHz and A1Az, H.Hz
curves) could be demonstrated in these seven patients.
After intravenous infusion of propranolol, induction of
sustained AV nodal reentrant tachycardia was possible in
only one patient (Case 3). Suppression of induction of sus-
tained tachycardia could be accounted for by propranolol-
induced abolition of the atrial echo zone in two patients
(Cases 8 and 11) and by propranolol-induced weak link in
the anterograde slow AV nodal pathway in five patients
(Cases 2, 3, 12, 14 and 15). In these latter five patients ,
the atrial echo zone was narrowed in three (Cases 2, 14 and
15) and widened in two (Cases 3 and 12).
During oral nadolol therapy, induction of sustained AV
nodal reentrant tachycardia was possible only in the patient
(Case 3) who failed to respond to intravenous propranolol.
Oral nadolol therapy , however, produced greater beta-ad-
renoceptor blockade as it completely abolished the atrial
echo zone in five patients (Cases 2, 8, II, 12, 14 and 15).
During the control study , induction ofsustained AV nodal
reentrant tachycardia with programmed ventricular extra -
stimulation was possible in only one patient (Case 5) with
the fast-slow form of AV nodal reentry (Table 2). In this
patient , the initiation of the ventricular echo phenomenon
was associated with double atrial responses and was fol-
lowed by onset of sustained tachycardia (Fig. 1). Both in-
travenous propranolol and oral nadolol abolished the ven-
tricular echo zone, thereby preventing induction of AV nodal
reentry (Fig. 2 and 3).
Anterograde conduction properties. Both intravenous
propranolol and oral nadolol shifted the dual AV nodal
pathway conduct ion curves (A.Az, AzHz; A1Az, H.Hz) up-
ward and to the right by prolonging the conduction time
and increasing the effective and functional refractory periods
of the fast and slow AV nodal pathways. One such example
is shown in Figure 4. The effective refractory period of the
fast and slow AV nodal pathways was 324 ± 33 and 260
± 12 ms, respectively, during the control period , 420 ±
85 and 327 ± 31 ms, respectively, after propranolol (p <
0.02 and p < 0.01, respectively) and 509 ± 108 and 391
± 61 IDS, respectively , after nadolol (p < 0.001 and p <
0.0 I , respectively) . The functional refractory period of the
fast and slow AV nodal pathways was 419 ± 24 and 504
± 44 ms, respectively , during the control period , 488 ±
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Table 2. Electrophysiologic Data Before, After Intravenous Propranolol and During Oral Nadolol Therapy in Group I Patients (AV
nodal reentrant tachycardia)
Anterograde Conduction Properties (ms) Retrograde Conduction
Properties (ms)
Case
SCL DCL
(ms) (ms)
ERP
FP SP
FRP
FP SP
Critical
AH
Interval
Echo
Zone
VA
Interval
ERP
VACS
Echo
Zone
SVT
CL
lnduction (ms) Sustamability
N 1030
330 455 555
280 430 4802 C
P
780 600
890 600
600
350
420
450 575
240
355
290-350
(40)
340-360
(20)
180
180
215
270
330
430
(0 )
(0)
Yes
No
No
390 Yes
N 1000
C 770
P 885 <260 590 Yes
Yes
Yes
Yes
500
385
400
460
Yes
Yes
Yes
(0)
(0 )
(0)
(0)
320 330-3 80
<240
<240
<230
190
190
215
200
(0)
270- 290
(20)
270- 360
(90)
290- 390
(100)
250
200
330
380
280 620
290 <260 420 520
<260400
600
600
600
750C5
3
P 830 400 290 390
(0 )
240 340 No
N 1050 400 330 410
(0 )
255
(0)
340 No
340 <250 450 5108 C
P
580
670
500
500 420 330 490 530
290
(0)
240- 340
(100)
190
210
(0)
280
(0)
420
Yes
No
290 Yes
N 840 500 390 550
(0)
240
(0)
450 No
N 11 60
330 <260 430 550
420 340 500 580
II C
P
800
870
600
600
600 460 610
320
(0)
260- 300
(40)
340-400
(60)
210
220
240
(0)
320
(0)
360
(0)
450
Yes
No
430
570
Yes
No
N 950
12 C
P
650
780
600
600
600
350
420
440
270 440 51 0
330 500 540
360 51 0 590
290
340
(0)
280-320
(40)
340-400
(60)
220
260
280
(0)
310
(0)
380
(0)
420
Yes
Yes
No
360
420
Yes
No
N 1010
300 <250 390 420
41 0 360 51 0 590
14 C
p
750
890
600
600
600 420 530
320
380
(0)
260-300
(40)
350-380
(30)
21 0
230
260
(0)
340
(0)
360
(0)
400
Yes
No
No
41 0 Yes
N 960
320 <250 41 0 540
380 340 460 590
15 C
P
720
860
600
600
600 400 380 480 610
300
330
(0)
250- 320
(70)
350- 360
(1 0 )
21 0
250
270
(0)
320
(0)
390
(0)
470
Yes
No
No
340 Yes
(0) (0)
AV = atrioventricular, C = control, CL = cycle length; DCL = driving cycle length; ERP = effective refractory period, FP = fast AV nodal
pathway; FRP = functional refractory period, N = nadolol: P = propranolol, SCL = sinus cycle length; SP = slow AV nodal pathway; SVT =
supravcntncular tachycardia, VA = ventnculoatrial, VACS = ventnculoatnal conduction system, ( ) = width of echo zone; - = absent or not
applicable,
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Table 3. Electrophysiologic Data Before, After Intravenous Propranolol and During Oral Nadolol Therapy in Group II Patients (AV
reciprocating tachycardia)
Antegrade Conduction
Properties (ms) Retrograde Conduction Properties (ms) SVT
Case
SCL DCL ERP
(ms) (ms) AVN
ERP
AP
Echo
Zone
VA ERP
Interval VACS
ERP
AP
Echo
Zone
CL
lnducuon (ms) Sustamability
C
p
720
650
600
600
<260
<250
(0)
190
200
<190
<210
< 190 200-320
(120)
<210
Yes
No
400 Yes
(0) (0)
N 900 600 <270 200 <230 No
N 1070 600
P 980 500
P 750 600
P 900 600
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
Yes
Yes
330
385
300
475
375
300
360
400
320
340
430
370
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
(0)
(0)
(0)
320-400
(80)
290 300-370
(70)
300 310-370
(30)
310-320
(10)
320
(0)
(0)
290
(0)
280 290-320
(30)
360
350
(0)
270 280-400
(120)
300 310-450
(130)
290
290
280
280
320
300
290
350
300
280
310
360
350
230
250
240
220
180
190
190
180
210
190
180
230
220
(0)
<250 >600 250-310
(60)
<260 >600 260-330
(70)
290 >600 290-370
(80)
290 300
(0)
280
(0)
230 >600 240-300
(60)
270 >600 280-370
(90)
330 >600 340-360
(20)
<220 >600 220-270
(50)
<230 >600 230-280
(50)
<240 >600 240-300
(60)
<260 <310 270-310
(40)
270 320 280-310
(30)
500790
C 700 600
P 750 600
C
C 880 500
C 670 600
N 1190 500
C 740 600
N 1050 600
N 1030 600
7
4
6
9
10
P 850 500 270 220 280 280 No
(0) (0)
N 1050 500 290 200 260 No
13 C
P
N
810 600
960 600
1150 600
(0)
<250
(0)
260
(0
<270
(0)
180
190
180
(0)
<190 <190 190-260
(70)
<200 <200 200-280
(80)
<200 200-310
(110)
Yes
Yes
Yes
280
300
340
Yes
Yes
Yes
AP = accessory pathway; AVN = atnoventricular node; other abbreviations as in Table 2.
60 and 568 ± 26 ms, respectively, after propranolol (p <
0.01 and p < 0.02, respectively) and 538 ::t 73 and 584
± 34 ms, respectively, after nadolol (p < 0.01 and p <
0.001, respectively). The anterograde fast AV nodal path-
way conduction was abolished by intravenous propranolol
in one patient (Case 3) and by oral nadolol in five patients
(Cases 2, 3, 8, 11 and 14) (Fig, 4),
Retrograde conduction properties. During the control
study, all patients had intact ventriculoatrial (VA) conduc-
tion during basic ventricular drive, Both intravenous pro-
pranolol and oral nadolol increased VA conduction time and
the effective refractory period of the VA conduction system
(presumably retrograde fast AV nodal pathway). However,
these effects were more pronounced during oral nadolol
lACC Vol 2, No.5
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Figure 1. Case 5. Initiation of atnoventricular (AV) nodal reen-
trant tachycardia of the fast-slow form during the control study.
A, During right ventricular pacing at a cycle length (S, - Sl) of
400 ms, a ventncular premature beat (S2) with a premature cou-
pling interval (SIS2) of 380 ms initiates an onset of AV nodal
reentrant tachycardia using a fast AV nodal pathway for antero-
grade conduction and a slow AV nodal pathway for retrograde
conduction. Note that the ventricular premature beat (S2) induces
double atrial responses presumably by way of a retrograde fast
and a retrograde slow AV nodal pathway. B, Progressive short-
ening of the premature coupling interval (SIS2) continues to initiate
onset of AV nodal reentrant tachycardia of the fast-slow form until
ventriculoatrial conduction fails at the premature coupling interval
of 320 ms. The shortest premature coupling interval that initiates
an onset of the tachycardia is 330 ms. The tachycardia cycle length
is 500 ms. In this figure and In Figures 2 and 3, electrocardio-
graphic leads I, II and VI are simultaneously recorded with intra-
cardiac high nght atrial (HRA), His bundle (HBE) and proximal
coronary sinus (CSp) electrographic leads. A = atrial electrogram;
Ae = atrial echo; H = His bundle potential. The ventriculoatrial
conduction time measured from the stimulus (Sl) to the onset of
high right atrial (HRA) electrogram is 215 ms.
therapy than after intravenous infusion of propranolol. The
VA conduction time was 203 ± 14 ms during the control
period, 223 ± 28 ms after propranolol (p < 0.02) and 245
± 27 ms after nadolol (p < 0.001). The effective refractory
period of the VA conduction system was 229 ± 36 ms
during the control period, 353 ± 54 ms after propranolol
(p < 0.01) and 406 ± 78 ms after nadolol (p < 0.001).
AV Reciprocating Tachycardia (Group II)
Of the seven patients in group 11, four (Cases I, 7, 10
and 13) had manifest and three (Cases 4, 6 and 9) had
concealed Wolff-Parkinson-White syndrome (14).
Inducibility of AV reciprocating tachycardia. During
the control study, programmed atrial extrastimulation in-
duced the atrial echo phenomenon and sustained AV recip-
rocating tachycardia in four patients: one (Case 7) with
manifest and three (Cases 4,6 and 9) with concealed Wolff-
Parkinson-White syndrome. Programmed ventricular ex-
trastimulation induced the ventricular echo phenomenon and
sustained AV reciprocating tachycardia in five patients (Cases
1,4,7, 10 and 13) (Table 3).
Intravenous infusion of propranolol suppressed the in-
ducibility of sustained AV reciprocating tachycardia in three
patients and was associated with disappearance of the ven-
tricular echo phenomenon in two (Cases I and 10) and
induction of nonsustained AV reciprocation in one (Case
7). In the remaining four patients (Cases 4, 6, 9 and 13),
the atrial or ventricular echo phenomenon, or both, per-
sisted, as did the inducibility of sustained AV reciprocating
tachycardia. However, because of propranolol-induced pro-
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Figure 2. Same case as in Figure I. Effects of
intravenous propranolol on the inducibility of
thefast-slow formof atrioventricular (AV) nodal
reentrant tachycardia. A. After intravenous in-
fusion of propranolol (0.2 rug/kg). a ventricular
premature beat (S2) with a premature coupling
interval (SIS2) of380 msduring nghtventricular
pacing at a cyclelength (SISI ) of 400ms induces
only one atrial response and fail s to initiate an
onsetof the tachycardia compared withthatshown
in Figure IA. Furthermore, the ventnculoatrial
(VA) conduction time during the basic drive is-
lengthened from215 to 240ms. B. The effective
refractory period of the VA conduction system
(presumably retrograde fast AV nodal pathway)
is also increased from 320 to 340 ms. The ven-
tricular echo zone is completely abolished by
intravenous propranolol. Abbreviations as in
Figure I.
D
HRA
HBE A H ~
longation of AV nodal conduction time, the rates of AV
reciprocating tachycardia were slower than those observed
during the control study.
Oral nadolol therapy abolished the atrial echo phenom-
enon in one patient (Case 7) and the ventricular echo phe-
nomenon in three other patients (Cases I , 4 and 10); how-
ever, it induced the ventricular echo phenomenon that had
not been present in one patient (Case 6). Overall, the in-
ducibility of sustained AV reciprocating tachycardia was
abolished in only three patients (Cases I , 7 and 10). Of
note, the four patients (Cases 4,6,9 and 13) with persistent
inducibility of sustained AV reciprocating tachycardia after
nadolol therapy were the same four patients who failed to
respond to intravenous propranolol.
Anterograde conduction properties. Anterograde
conduction over the accessory AV pathway precluded ad-
equate assessment of AV nodal conduction properties in
three patients (Cases I. 10 and 13). However, depressive
effects of intravenous propranolol and oral nadolol on the
AV node were evident in the three patients with concealed
accessory AV pathways (Table 3). The findings were similar
to those observed in patients in group 1.
Neither intravenous propranolol nor oral nadolol sig-
nificantly affected the anterograde conduction properties of
accessory AV pathways in the four patients with manifest
Wolff-Parkinson-White syndrome (Table 3). The antero-
5OOm.. I
grade effective refractory period of the accessory AV path-
ways measured 4 14 ± 175 ms during the control period,
413 ± 170 ms after propranolol and 419 ± 170 ms after
nadolol.
Retrograde conduction properties. All seven patients
exhibited VA conduction by way of a left-sided accessory
AV pathway as evidenced by the presence of an abnormal
sequence of retrograde atrial activation (left atrial activation
preceded low septal right atrial and high right atrial acti-
vation) during the control study. The VA conduction time
found in the control study remained unchanged after intra-
venous infusion of propranolol and after oral nadolol therapy
(20I ± 27, 209 ± 21 and 200 ± 19 ms. respectively) and
the effective refractory period of the VA conduction system
(accessory AV pathway) also was not significantly altered
(271 ± 6 1 ms during the control period, 274 ± 55 ms after
propranolol and 277 ± 51 ms after nadolol).
Follow-Up
During the 5 to 8 (mean 6.8) days of oral nadolol therapy.
none of the patients had spontaneous occurrence of supra-
ventricular tachycardia before repeat electrophysiologic
studies. The 10 patients who showed a favorable response
with loss of the inducibility of sustained tachycardia re-
mained on oral nadolol therapy. During a follow-up period
of 9 to 15 (mean 11.5) months, all 10 patients experienced
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Figure 3. Same case as in Figures I and 2.
Effects of oral nadolol on the inducibility of the
fast-slow form of atrioventricular nodal reentrant
tachycardia. A. After oral nadolol (120 mg/day)
for 7 days, a ventricular premature beat (S2) with
a premature coupling interval (S,S2) of 380 ms
during right ventricular pacing at a cycle length
(S.S.) of 400 ms induces only one atrial response
and fails to initiate an onset of the tachycardia
compared with that shown in Figure IA. The
ventriculoatrial (VA) conduction time during the
basic drive is lengthened from 215 to 255 ms.
B, The effective refractory period of the VA
conduction system is also increased from 320 to
340 ms. The ventricular echo zone is completely
abolished by oral nadolol therapy. The effects
of oral nadolol are comparable with those of
intravenous propranolol (see Fig. 2A and B).
RV = right ventricular electrogram.
symptomatic improvement- 7 remained asymptomatic and
3 had occasional short-lasting episodes of palpitation. Of
the fivepatients who did not lose inducibility of tachycardia,
two were subsequently treated with quinidine and nadolol,
two were treated with digitalis and verapamil and one was
treated with amiodarone because of prior failure to respond
to conventional drugs. These five patients had all done well
during a follow-up period of 9 to 12 (mean 9.8) months.
Discussion
The effectiveness of beta-adrenoceptor blocking agents
in the treatment of supraventricular tachyarrhythmias is at-
tributable to their depressive action on the atrioventricular
(AV) node. Electrophysiologic studies (18- 2 1) have shown
that propranolol may suppress the inducibility of supraven-
tricular tachycardia by increasing AV nodal refractoriness
or slowing the rate of tachycardia by prolonging AV nodal
conduction time. The results of our study are in accordance
with these findings. In addition, our study demonstrated that
oral nadolol administered once daily exerted electrophysi-
ologic effects similar to those of intravenous propranolol.
Thus, oral nadolol may be useful for chronic prophylaxis
of recurrent supraventricular tachycardia.
Effects of intravenous propranolol. In a group of 12
patients with paroxysmal supraventricular tachycardia, Wu
et al. (18) observed variable effects of intravenous pro-
pranolol on the inducibility of tachycardia. Six of the their
12 patients had dual AV nodal pathway conduction curves
(discontinuous AIA2 , A2H 2; A,A2 , H,H2 curves) revealed
with programmed atrial extrastimulation. Intravenous pro-
pranolol shifted the curves upward and to the right by pro-
longing anterograde refractory period and conduction time
of both fast and slow AV nodal pathways. Furthermore,
int ravenous propranolol increased refractoriness of the ret-
rograde fast AV nodal pathway. thereby abolishing the atrial
echo pehnomenon in two of the six patients. However,
intravenous propranolol prevented induction of sustained
tachycardia in only four of nine patients who had inducible
sustained tachycardia.
In a group of 18 patients with AV reciprocating tachy-
cardia using an accessory AV pathway for retrograde con-
duction, Denes et al. (19) demonstrated that intravenous
propranolol had no significant effect on the electrophysio-
logic properties of the accessory AV pathway and prevented
induction of sustained AV reciprocating tachycardia in only
4 of 14 patients who had had inducible sustained tachy-
cardia. Similarly, in a group of 14 patients with the Wolff-
Parkinson-White syndrome, Barrett et al. (20) found that
intravenous propranolol slowed the rate of AV reciprocating
tachycardia by prolonging AV nodal conduction time, but
failed to suppress its inducibility in all of their patients.
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They concluded that intravenous propranolol was unlikely
to be effective for the treatment of AV reciprocating
tachycardia.
In the present study, intravenous propranolol prevented
induction of sustained tachycardia in seven of the eight
patients with AV nodal reentrant tachycardia and in three
of the seven patients with AV reciprocating tachycardia.
The higher rate of success than those reported by others in
suppressing the inducibility of sustained tachycardia could
be ascribed to the higher dose of intravenous propranolol
used in the present study (0.2 mg/kg as compared with 0.1
mg/kg used in other studies [18-20]).
Effects of oral nadolol. Although the extent of beta-
adrenoceptor blockade could not be determined precisely,
oral nadolol in single, daily doses of 80 to 160 mg for 5 to
8 (mean 6.8) days exerted electrophysiologic effects at least
comparable with those of intravenous propranolol, 0.2 mglkg.
In fact, oral nadolol therapy exhibited more beta-adreno-
ceptor blockade than intravenous propranolol as evidenced
by slower rest sinus rate and more depressed AV nodal
conduction achieved during oral nadolol therapy (Tables 2
and 3). Ten patients (seven with AV nodal reentry and three
with AV reciprocation) who responded to intravenous pro-
pranolol also responded to oral nadolol with loss of the
inducibility of sustained tachycardia, and the remaining five
patients (one with AV nodal reentry and four with AV
reciprocation) who did not respond to intravenous propran-
olol also failed to respond to oral nadolol with persistence
of the inducibility of sustained tachycardia. The higher rate
of failure in suppressing the tachycardia inducibility in pa-
tients with AV reciprocation compared with those with AV
nodal reentry could be explained by the lack of effect of
Figure 4. Case 2. Effects of intravenous propranolol and oral
nadolol on dual atrioventricular (AV) nodal pathway conduction.
A, A1Az, AzHz and AIAz, H1Hz curves during high right atrial
(HRA) pacing at a cycle length (CL) of 600 ms. The circles
represent responses during the control study (solid circles = re-
sponses without atrial echoes; open circles = responses with atrial
echoes), the triangles represent responses after intravenous pro-
pranolol (solid triangles = responses without atrial echoes; open
triangles = responses with atrial echoes) and the squares rep-
resent responses after oral nadolo!. During the control study, the
AV nodal conduction time (AH) is 110 ms and the effective and
functional refractory periods of the fast AV nodal pathway are 350
and 430 ms, respectively, and those of the slow AV nodal pathway
are 280 and 480 rns, respectively. Induction of atrial echoes (290
to 350 ms) is followed by imtiation of sustained AV nodal reentrant
tachycardia of the slow-fast form. After intravenous tnfusion of
propranolol, the AV nodal conduction time (AH) is 120 ms and
the effective and functional refractory periods of the fast AV nodal
pathway are 420 and 455 ms, respectively, and those of the slow
AV nodal pathway are 330 and 555 ms, respectively. Induction
of single atrial echoes (340 to 360 ms) is not followed by initiation
of tachycardia. After oral nadolol therapy, the AV nodal conduc-
tion time is lengthened to 270 ms and the AIAz, AzHz and A1Az,
H1Hz curves become smooth, suggestive of only slow AV nodal
pathway conduction. The effective and functional refractory pe-
riods of the slow AV nodal pathway are 450 and 575 ms, respec-
tively. No atrial echoes are induced.
B, VIVz, VzAz curves dunng right ventricular (RV) pacing at
a cycle length of 600 ms. The solid circles represent responses
during the control study, the solid triangles represent responses
after intravenous propranolol and the solid squares represent re-
sponses after oral nadolo!. The ventriculoatrial (VA) conduction
time (VIAl) is 180 ms and its effective refractory period is 270
ms. After intravenous administration of propranolol, the VA con-
duction time rernams 180 ms but its effective refractory period is
increased to 330 ms. During oral nadolol therapy, the VA con-
duction time is lengthened to 215 ms and its effective refractory
period is prolonged to 430 ms. No ventricular echoes are induced
during the control period, or after intravenous propranolol or oral
nadolo!.
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beta-adrenoceptor blockade on the electrophysiologic prop-
erties of the accessory AV pathway or by the coexistence
of enhanced AV nodal conduction in certain patients (22- 24),
or by both.
Clinical implications. Nadolol is a noncardioselective
beta-adrenoceptor blocking agent. Although in oral form it
is only 30% absorbed, it possesses a unique pharmacologic
property in that it has the longest plasma half-life (14 to 24
hours) of all known beta-adrenoceptor blocking agents (1-3).
Previous studies have shown that oral nadolol in single,
daily doses is effective for the treatment of hypertension
and angina pectoris (4-8). The present study has further
demonstrated that oral nadolol administered once daily may
suppress the inducibility of supraventricular tachycardia.
For better patient compliance, oral nadolol in once-daily
doses is thus particularly useful in patients withconcomitant
hypertension, angina pectoris and supraventricular tachy-
cardia.
Our study has also demonstrated that the efficacy of oral
nadolol therapy can be predicted by the response to intra-
venous infusion of propranolol at the dosage of 0.2 mg/kg.
This information is useful in managing patients who require
serial pharmacologic testing to select an effective medical
regimen . Oral nadolol therapy is unlikely to be effective in
patients who fail to respond to intravenous propranolol as
tested by programmed electrical stimulation.
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